Modern approaches to cervical cancer screening (a review)

Authors

DOI:

https://doi.org/10.14739/2310-1237.2023.1.264035

Keywords:

cervix, precancerous cervical pathology, cervical cancer, human papilloma virus, cervical screening, cytologic method, HPV DNA test, colposcopy

Abstract

The aim – systematization of data from modern scientific sources and own knowledge and experience regarding the problems, advantages and prospects of the development of various methods of diagnosing pathological conditions of the cervix.

The relevance of the problem of cervical cancer is beyond doubt, which is confirmed by the annual data of the official statistics and recommendations of WHO, European experts and relevant national recommendations. The analysis and generalization of information from the specialized literature regarding the assessment of problems and prospects for the development of leading methods of cervical screening in order to reduce the number of cervical cancer cases in the world is a priority task of the expert society.

Currently, the most recommended approach to cervical screening is to combine HPV testing with cytology but separate testing for HPV is the most promising. Colposcopy remains the only confirmatory method of diagnosing cervical pathology, subject to mandatory cervical biopsy and histopathological examination of the biopsy. Standardization of classifications and terminology in the assessment of cytological, histopathological and colposcopic conclusions will allow to reach an understanding in the issues of optimal management tactics for patients with cervical pathology.

Conclusions. Diagnosis of high-risk carcinogenic types of human papillomavirus is the most promising method of cervical screening in the near future. At the same time, at the moment, we consider it appropriate to use the cytology together with HPV testing, at least as a sorting method. Standardization of cytological/histopathological terminology should be done in accordance with the Bethesda 2014 system update.

Author Biographies

M. I. Pavliuchenko, Zaporizhzhia State Medical University, Ukraine

MD, PhD, Assosiate Professor of the Department of Obstetrics and Gynecology

Yu. Ya. Krut, Zaporizhzhia State Medical University, Ukraine

MD, PhD, DSc, Professor, Head of the Department of Obstetrics and Gynecology

V. H. Siusiuka, Zaporizhzhia State Medical University, Ukraine

MD, PhD, DSc, Assosiate Professor of the Department of Obstetrics and Gynecology

O. V. Deinichenko, Zaporizhzhia State Medical University, Ukraine

MD, PhD, Assistant of the Department of Obstetrics and Gynecology

References

  1. World Health Organization. (2020, November 17). Global strategy to accelerate the elimination of cervical cancer as a public health problem. https://www.who.int/publications/i/item/9789240014107
  2. Dürst, M., Gissmann, L., Ikenberg, H., & zur Hausen, H. (1983). A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proceedings of the National Academy of Sciences of the United States of America, 80(12), 3812-3815. https://doi.org/10.1073/pnas.80.12.3812
  3. Li, N., Franceschi, S., Howell-Jones, R., Snijders, P. J., & Clifford, G. M. (2011). Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. International journal of cancer, 128(4), 927-935. https://doi.org/10.1002/ijc.25396
  4. Xing, B., Guo, J., Sheng, Y., Wu, G., & Zhao, Y. (2021). Human Papillomavirus-Negative Cervical Cancer: A Comprehensive Review. Frontiers in oncology, 10, 606335. https://doi.org/10.3389/fonc.2020.606335
  5. Lee, J. E., Chung, Y., Rhee, S., & Kim, T. H. (2022). Untold story of human cervical cancers: HPV-negative cervical cancer. BMB reports, 55(9), 429-438. https://doi.org/10.5483/BMBRep.2022.55.9.042
  6. Petry, K. U., Liebrich, C., Luyten, A., Zander, M., & Iftner, T. (2017). Surgical staging identified false HPV-negative cases in a large series of invasive cervical cancers. Papillomavirus research (Amsterdam, Netherlands), 4, 85-89. https://doi.org/10.1016/j.pvr.2017.10.003
  7. Schiffman, M., & Wentzensen, N. (2016). A Suggested Approach to Simplify and Improve Cervical Screening in the United States. Journal of lower genital tract disease, 20(1), 1-7. https://doi.org/10.1097/LGT.0000000000000170
  8. Brisson, M., Kim, J. J., Canfell, K., Drolet, M., Gingras, G., Burger, E. A., Martin, D., Simms, K. T., Bénard, É., Boily, M. C., Sy, S., Regan, C., Keane, A., Caruana, M., Nguyen, D. T. N., Smith, M. A., Laprise, J. F., Jit, M., Alary, M., Bray, F., … Hutubessy, R. (2020). Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet, 395(10224), 575-590. https://doi.org/10.1016/S0140-6736(20)30068-4
  9. Sundström, K., & Elfström, K. M. (2020). Advances in cervical cancer prevention: Efficacy, effectiveness, elimination?. PLoS medicine, 17(1), e1003035. https://doi.org/10.1371/journal.pmed.1003035
  10. Meites, E., Szilagyi, P. G., Chesson, H. W., Unger, E. R., Romero, J. R., & Markowitz, L. E. (2019). Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR. Morbidity and mortality weekly report, 68(32), 698-702. https://doi.org/10.15585/mmwr.mm6832a3
  11. Reagan-Steiner, S., Yankey, D., Jeyarajah, J., Elam-Evans, L. D., Curtis, C. R., MacNeil, J., Markowitz, L. E., & Singleton, J. A. (2016). National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years – United States, 2015. MMWR. Morbidity and mortality weekly report, 65(33), 850-858. https://doi.org/10.15585/mmwr.mm6533a4
  12. Canfell, K., Kim, J. J., Brisson, M., Keane, A., Simms, K. T., Caruana, M., Burger, E. A., Martin, D., Nguyen, D. T. N., Bénard, É., Sy, S., Regan, C., Drolet, M., Gingras, G., Laprise, J. F., Torode, J., Smith, M. A., Fidarova, E., Trapani, D., Bray, F., … Hutubessy, R. (2020). Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet, 395(10224), 591-603. https://doi.org/10.1016/S0140-6736(20)30157-4
  13. Wang, J., Elfström, K. M., Andrae, B., Nordqvist Kleppe, S., Ploner, A., Lei, J., Dillner, J., Sundström, K., & Sparén, P. (2020). Cervical cancer case-control audit: Results from routine evaluation of a nationwide cervical screening program. International journal of cancer, 146(5), 1230-1240. https://doi.org/10.1002/ijc.32416
  14. Jansen, E. E. L., Zielonke, N., Gini, A., Anttila, A., Segnan, N., Vokó, Z., Ivanuš, U., McKee, M., de Koning, H. J., de Kok, I. M. C. M., & EU-TOPIA consortium (2020). Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review. European journal of cancer, 127, 207-223. https://doi.org/10.1016/j.ejca.2019.12.013
  15. Wentzensen, N., & Schiffman, M. (2014). Filling a gap in cervical cancer screening programmes. The Lancet. Oncology, 15(3), 249-251. https://doi.org/10.1016/S1470-2045(14)70073-7
  16. Massad, L. S., Einstein, M. H., Huh, W. K., Katki, H. A., Kinney, W. K., Schiffman, M., Solomon, D., Wentzensen, N., Lawson, H. W., & 2012 ASCCP Consensus Guidelines Conference (2013). 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Journal of lower genital tract disease, 17(5 Suppl 1), S1-S27. https://doi.org/10.1097/LGT.0b013e318287d329
  17. Huh, W. K., Ault, K. A., Chelmow, D., Davey, D. D., Goulart, R. A., Garcia, F. A., Kinney, W. K., Massad, L. S., Mayeaux, E. J., Saslow, D., Schiffman, M., Wentzensen, N., Lawson, H. W., & Einstein, M. H. (2015). Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Journal of lower genital tract disease, 19(2), 91-96. https://doi.org/10.1097/LGT.0000000000000103
  18. Canfell, K., Smith, M. A., & Bateson, D. J. (2021). Self-collection for HPV screening: a game changer in the elimination of cervical cancer. The Medical journal of Australia, 215(8), 347-348. https://doi.org/10.5694/mja2.51262
  19. Maver, P. J., & Poljak, M. (2020). Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clinical microbiology and infection, 26(5), 579-583. https://doi.org/10.1016/j.cmi.2019.09.006
  20. Cuzick, J., Cadman, L., Mesher, D., Austin, J., Ashdown-Barr, L., Ho, L., Terry, G., Liddle, S., Wright, C., Lyons, D., & Szarewski, A. (2013). Comparing the performance of six human papillomavirus tests in a screening population. British journal of cancer, 108(4), 908-913. https://doi.org/10.1038/bjc.2013.22
  21. Kinney, W., Wright, T. C., Dinkelspiel, H. E., DeFrancesco, M., Thomas Cox, J., & Huh, W. (2015). Increased cervical cancer risk associated with screening at longer intervals. Obstetrics and gynecology, 125(2), 311-315. https://doi.org/10.1097/AOG.0000000000000632
  22. Blatt, A. J., Kennedy, R., Luff, R. D., Austin, R. M., & Rabin, D. S. (2015). Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer cytopathology, 123(5), 282-288. https://doi.org/10.1002/cncy.21544
  23. Giorgi-Rossi, P., Arbyn, M., & Meijer, C. J. (2015). Cervical cancer screening by human papillomavirus testing followed by cytology triage. JAMA internal medicine, 175(6), 1068. https://doi.org/10.1001/jamainternmed.2015.0592
  24. Saei Ghare Naz, M., Kariman, N., Ebadi, A., Ozgoli, G., Ghasemi, V., & Rashidi Fakari, F. (2018). Educational Interventions for Cervical Cancer Screening Behavior of Women: A Systematic Review. Asian Pacific journal of cancer prevention : APJCP, 19(4), 875-884. https://doi.org/10.22034/APJCP.2018.19.4.875
  25. Rahatgaonkar, V. G., Deshpande, A. A., & Oka, G. A. (2021). Screening for cervical cancer in HIV-infected women: A review of literature. Indian journal of cancer, 58(3), 317-325. https://doi.org/10.4103/ijc.IJC_888_19
  26. Salehiniya, H., Momenimovahed, Z., Allahqoli, L., Momenimovahed, S., & Alkatout, I. (2021). Factors related to cervical cancer screening among Asian women. European review for medical and pharmacological sciences, 25(19), 6109-6122. https://doi.org/10.26355/eurrev_202110_26889
  27. Cho, H. W., Hong, J. H., & Lee, J. K. (2021). Human papillomavirus testing as a primary screening tool for cervical cancer. Journal of gynecologic oncology, 32(3), e56. https://doi.org/10.3802/jgo.2021.32.e56
  28. Bruni, L., Serrano, B., Roura, E., Alemany, L., Cowan, M., Herrero, R., Poljak, M., Murillo, R., Broutet, N., Riley, L. M., & de Sanjose, S. (2022). Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. The Lancet. Global health, 10(8), e1115-e1127. https://doi.org/10.1016/S2214-109X(22)00241-8
  29. Gage, J. C., Schiffman, M., Katki, H. A., Castle, P. E., Fetterman, B., Wentzensen, N., Poitras, N. E., Lorey, T., Cheung, L. C., & Kinney, W. K. (2014). Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. Journal of the National Cancer Institute, 106(8), dju153. https://doi.org/10.1093/jnci/dju153
  30. Fontham, E. T. H., Wolf, A. M. D., Church, T. R., Etzioni, R., Flowers, C. R., Herzig, A., Guerra, C. E., Oeffinger, K. C., Shih, Y. T., Walter, L. C., Kim, J. J., Andrews, K. S., DeSantis, C. E., Fedewa, S. A., Manassaram-Baptiste, D., Saslow, D., Wender, R. C., & Smith, R. A. (2020). Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA: a cancer journal for clinicians, 70(5), 321-346. https://doi.org/10.3322/caac.21628
  31. Castle, P. E., Wheeler, C. M., Campos, N. G., Sy, S., Burger, E. A., Kim, J. J., & New Mexico HPV Pap Registry Steering Committee (2018). Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. Preventive medicine, 111, 177-179. https://doi.org/10.1016/j.ypmed.2018.03.011
  32. Isaka, Y., Hori, A., Tanaka, R., & Ichikawa, M. (2021). Alleviating psychological distress associated with a positive cervical cancer screening result: a randomized control trial. BMC women’s health, 21(1), 64. https://doi.org/10.1186/s12905-021-01207-6
  33. Bergeron, C., Ronco, G., Reuschenbach, M., Wentzensen, N., Arbyn, M., Stoler, M., & von Knebel Doeberitz, M. (2015). The clinical impact of using p16(INK4a) immunochemistry in cervical histopathology and cytology: an update of recent developments. International journal of cancer, 136(12), 2741-2751. https://doi.org/10.1002/ijc.28900
  34. Zhao, C., Moriarty, A. T., Ghofrani, M., Husain, M., Tambouret, R. H., Laucirica, R., Laser, A., Fischer, A., Ocal, I. T., Souers, R. J., Russell, D. K., Fan, F., & Crothers, B. A. (2015). Human papillomavirus testing and reporting rates in 2012: results of a College of American Pathologists national survey. Archives of pathology & laboratory medicine, 139(6), 757-761. https://doi.org/10.5858/arpa.2014-0393-CP
  35. Wentzensen, N., Fetterman, B., Castle, P. E., Schiffman, M., Wood, S. N., Stiemerling, E., Tokugawa, D., Bodelon, C., Poitras, N., Lorey, T., & Kinney, W. (2015). p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women. Journal of the National Cancer Institute, 107(12), djv257. https://doi.org/10.1093/jnci/djv257
  36. Cox, J. T., Castle, P. E., Behrens, C. M., Sharma, A., Wright, T. C., Jr, Cuzick, J., & Athena HPV Study Group (2013). Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. American journal of obstetrics and gynecology, 208(3), 184.e1-184.e11. https://doi.org/10.1016/j.ajog.2012.11.020
  37. Wentzensen, N., Sun, C., Ghosh, A., Kinney, W., Mirabello, L., Wacholder, S., Shaber, R., LaMere, B., Clarke, M., Lorincz, A. T., Castle, P. E., Schiffman, M., & Burk, R. D. (2012). Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. Journal of the National Cancer Institute, 104(22), 1738-1749. https://doi.org/10.1093/jnci/djs425
  38. Sawaya, G. F., Smith-McCune, K., & Kuppermann, M. (2019). Cervical Cancer Screening: More Choices in 2019. JAMA, 321(20), 2018-2019. https://doi.org/10.1001/jama.2019.4595
  39. Marcus, P. M., Prorok, P. C., Miller, A. B., DeVoto, E. J., & Kramer, B. S. (2015). Conceptualizing overdiagnosis in cancer screening. Journal of the National Cancer Institute, 107(4), djv014. https://doi.org/10.1093/jnci/djv014
  40. FDA. (2020, March 10). PMA P190024: FDA Summary of Safety and Effectiveness Data. https://www.accessdata.fda.gov/cdrh_docs/pdf19/P190024B.pdf
  41. Darragh, T. M., Colgan, T. J., Cox, J. T., Heller, D. S., Henry, M. R., Luff, R. D., McCalmont, T., Nayar, R., Palefsky, J. M., Stoler, M. H., Wilkinson, E. J., Zaino, R. J., Wilbur, D. C., & Members of LAST Project Work Groups (2012). The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Journal of lower genital tract disease, 16(3), 205-242. https://doi.org/10.1097/LGT.0b013e31825c31dd
  42. Nayar, R., & Wilbur, D. C. (2015). The Pap test and Bethesda 2014. Cancer cytopathology, 123(5), 271-281. https://doi.org/10.1002/cncy.21521
  43. Nayar, R., & Wilbur, D. C. (2015). The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes (pp. 1-321). Springer International Publishing. https://doi.org/10.1007/978-3-319-11074-5
  44. Giorgi Rossi, P., Carozzi, F., Ronco, G., Allia, E., Bisanzi, S., Gillio-Tos, A., De Marco, L., Rizzolo, R., Gustinucci, D., Del Mistro, A., Frayle, H., Confortini, M., Iossa, A., Cesarini, E., Bulletti, S., Passamonti, B., Gori, S., Toniolo, L., Barca, A., Bonvicini, L., … the New Technology for Cervical Cancer 2 Working Group (2021). p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women. Journal of the National Cancer Institute, 113(3), 292-300. https://doi.org/10.1093/jnci/djaa105
  45. Clarke, M. A., Cheung, L. C., Castle, P. E., Schiffman, M., Tokugawa, D., Poitras, N., Lorey, T., Kinney, W., & Wentzensen, N. (2019). Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women. JAMA oncology, 5(2), 181-186. https://doi.org/10.1001/jamaoncol.2018.4270
  46. Yang, D. X., Soulos, P. R., Davis, B., Gross, C. P., & Yu, J. B. (2018). Impact of Widespread Cervical Cancer Screening: Number of Cancers Prevented and Changes in Race-specific Incidence. American journal of clinical oncology, 41(3), 289-294. https://doi.org/10.1097/COC.0000000000000264
  47. Hammer, A., & Gravitt, P. (2021). Clinical implications of transitioning from cytology to human papillomavirus-based cervical cancer screening. Acta obstetricia et gynecologica Scandinavica, 100(3), 371-372. https://doi.org/10.1111/aogs.14107
  48. Koliopoulos, G., Nyaga, V. N., Santesso, N., Bryant, A., Martin-Hirsch, P. P., Mustafa, R. A., Schünemann, H., Paraskevaidis, E., & Arbyn, M. (2017). Cytology versus HPV testing for cervical cancer screening in the general population. The Cochrane database of systematic reviews, 8(8), CD008587. https://doi.org/10.1002/14651858.CD008587.pub2
  49. Demarco, M., Hyun, N., Carter-Pokras, O., Raine-Bennett, T. R., Cheung, L., Chen, X., Hammer, A., Campos, N., Kinney, W., Gage, J. C., Befano, B., Perkins, R. B., He, X., Dallal, C., Chen, J., Poitras, N., Mayrand, M. H., Coutlee, F., Burk, R. D., Lorey, T., … Schiffman, M. (2020). A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine, 22, 100293. https://doi.org/10.1016/j.eclinm.2020.100293
  50. Guan, P., Howell-Jones, R., Li, N., Bruni, L., de Sanjosé, S., Franceschi, S., & Clifford, G. M. (2012). Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. International journal of cancer, 131(10), 2349-2359. https://doi.org/10.1002/ijc.27485
  51. Thomsen, L. T., Frederiksen, K., Munk, C., Junge, J., Castle, P. E., Iftner, T., & Kjaer, S. K. (2014). High-risk and low-risk human papillomavirus and the absolute risk of cervical intraepithelial neoplasia or cancer. Obstetrics and gynecology, 123(1), 57-64. https://doi.org/10.1097/AOG.0000000000000056
  52. Schiffman, M., Burk, R. D., Boyle, S., Raine-Bennett, T., Katki, H. A., Gage, J. C., Wentzensen, N., Kornegay, J. R., Aldrich, C., Tam, T., Erlich, H., Apple, R., Befano, B., & Castle, P. E. (2015). A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. Journal of clinical microbiology, 53(1), 52-59. https://doi.org/10.1128/JCM.02116-14
  53. Hu, Z., & Ma, D. (2018). The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer medicine, 7(10), 5217-5236. https://doi.org/10.1002/cam4.1501
  54. Schiffman, M., & Wentzensen, N. (2021). The Orderly Incorporation of Continuing Technologic Advances Into Cervical Cancer Screening. Journal of the National Cancer Institute, 113(3), 231-233. https://doi.org/10.1093/jnci/djaa106
  55. Wentzensen, N., Walker, J. L., Gold, M. A., Smith, K. M., Zuna, R. E., Mathews, C., Dunn, S. T., Zhang, R., Moxley, K., Bishop, E., Tenney, M., Nugent, E., Graubard, B. I., Wacholder, S., & Schiffman, M. (2015). Multiple biopsies and detection of cervical cancer precursors at colposcopy. Journal of clinical oncology, 33(1), 83-89. https://doi.org/10.1200/JCO.2014.55.9948
  56. Davies, K. R., Cantor, S. B., Cox, D. D., & Follen, M. (2015). An alternative approach for estimating the accuracy of colposcopy in detecting cervical precancer. PloS one, 10(5), e0126573. https://doi.org/10.1371/journal.pone.0126573
  57. Gage, J. C., Katki, H. A., Schiffman, M., Castle, P. E., Fetterman, B., Poitras, N. E., Lorey, T., Cheung, L. C., Behrens, C., Sharma, A., Zhao, F. H., Cuzick, J., Yang, Z. H., & Kinney, W. K. (2014). The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management. Cancer cytopathology, 122(11), 842-850. https://doi.org/10.1002/cncy.21463
  58. Katki, H. A., Schiffman, M., Castle, P. E., Fetterman, B., Poitras, N. E., Lorey, T., Cheung, L. C., Raine-Bennett, T., Gage, J. C., & Kinney, W. K. (2013). Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results. Journal of lower genital tract disease, 17(5 Suppl 1), S50-S55. https://doi.org/10.1097/LGT.0b013e3182854282
  59. Katki, H. A., Schiffman, M., Castle, P. E., Fetterman, B., Poitras, N. E., Lorey, T., Cheung, L. C., Raine-Bennett, T., Gage, J. C., & Kinney, W. K. (2013). Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. Journal of lower genital tract disease, 17(5 Suppl 1), S56-S63. https://doi.org/10.1097/LGT.0b013e318285437b
  60. Schiffman, M., Vaughan, L. M., Raine-Bennett, T. R., Castle, P. E., Katki, H. A., Gage, J. C., Fetterman, B., Befano, B., & Wentzensen, N. (2015). A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Gynecologic oncology, 138(3), 573-578. https://doi.org/10.1016/j.ygyno.2015.06.040
  61. Schiffman, M., & Wentzensen, N. (2015). Transitioning to a new era in cervical cancer screening. Gynecologic oncology, 136(2), 175-177. https://doi.org/10.1016/j.ygyno.2015.01.538
  62. Reid, J. L., Wright, T. C., Jr, Stoler, M. H., Cuzick, J., Castle, P. E., Dockter, J., Getman, D., & Giachetti, C. (2015). Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study. American journal of clinical pathology, 144(3), 473-483. https://doi.org/10.1309/AJCPHVD7MIP3FYVV
  63. Bedell, S. L., Goldstein, L. S., Goldstein, A. R., & Goldstein, A. T. (2020). Cervical Cancer Screening: Past, Present, and Future. Sexual medicine reviews, 8(1), 28-37. https://doi.org/10.1016/j.sxmr.2019.09.005
  64. Xue, P., Ng, M. T. A., & Qiao, Y. (2020). The challenges of colposcopy for cervical cancer screening in LMICs and solutions by artificial intelligence. BMC medicine, 18(1), 169. https://doi.org/10.1186/s12916-020-01613-x
  65. Katki, H. A., Gage, J. C., Schiffman, M., Castle, P. E., Fetterman, B., Poitras, N. E., Lorey, T., Cheung, L. C., Raine-Bennett, T., & Kinney, W. K. (2013). Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less. Journal of lower genital tract disease, 17(5 Suppl 1), S69-S77. https://doi.org/10.1097/LGT.0b013e31828543b1
  66. Kaufman, H. W., Alagia, D. P., Chen, Z., Onisko, A., & Austin, R. M. (2020). Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States. American journal of clinical pathology, 154(4), 510-516. https://doi.org/10.1093/ajcp/aqaa074
  67. Perkins, R. B., Guido, R. L., Saraiya, M., Sawaya, G. F., Wentzensen, N., Schiffman, M., & Feldman, S. (2021). Summary of Current Guidelines for Cervical Cancer Screening and Management of Abnormal Test Results: 2016-2020. Journal of women’s health (2002), 30(1), 5-13. https://doi.org/10.1089/jwh.2020.8918
  68. Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., Berkhof, J., Peto, J., Meijer, C. J., & International HPV screening working group (2014). Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet, 383(9916), 524-532. https://doi.org/10.1016/S0140-6736(13)62218-7
  69. World Health Organization. (2021, July 6). WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, Second edition. https://www.who.int/publications/i/item/9789240030824
  70. Arbyn, M., Smith, S. B., Temin, S., Sultana, F., Castle, P., & Collaboration on Self-Sampling and HPV Testing (2018). Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ (Clinical research ed.), 363, k4823. https://doi.org/10.1136/bmj.k4823
  71. Hawkes, D., Keung, M. H. T., Huang, Y., McDermott, T. L., Romano, J., Saville, M., & Brotherton, J. M. L. (2020). Self-Collection for Cervical Screening Programs: From Research to Reality. Cancers, 12(4), 1053. https://doi.org/10.3390/cancers12041053
  72. Song, F., Du, H., Xiao, A., Wang, C., Huang, X., Liu, Z., Zhao, M., Men, H., & Wu, R. (2020). Evaluating the performance of three different cervical cancer screening modalities in a large prospective population-based cohort. Journal of infection and public health, 13(11), 1780-1786. https://doi.org/10.1016/j.jiph.2020.08.008
  73. Katki, H. A., Schiffman, M., Castle, P. E., Fetterman, B., Poitras, N. E., Lorey, T., Cheung, L. C., Raine-Bennett, T., Gage, J. C., & Kinney, W. K. (2013). Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. Journal of lower genital tract disease, 17(5 Suppl 1), S36-S42. https://doi.org/10.1097/LGT.0b013e3182854253
  74. Perkins, R. B., Guido, R. S., Castle, P. E., Chelmow, D., Einstein, M. H., Garcia, F., Huh, W. K., Kim, J. J., Moscicki, A. B., Nayar, R., Saraiya, M., Sawaya, G. F., Wentzensen, N., Schiffman, M., & 2019 ASCCP Risk-Based Management Consensus Guidelines Committee (2020). 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of lower genital tract disease, 24(2), 102-131. https://doi.org/10.1097/LGT.0000000000000525
  75. Katki, H. A., Schiffman, M., Castle, P. E., Fetterman, B., Poitras, N. E., Lorey, T., Cheung, L. C., Raine-Bennett, T., Gage, J. C., & Kinney, W. K. (2013). Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. Journal of lower genital tract disease, 17(5 Suppl 1), S28-S35. https://doi.org/10.1097/LGT.0b013e318285423c
  76. Schiffman, M., & Wentzensen, N. (2021). Cervical Screening Performance. American journal of clinical pathology, 155(4), 616-620. https://doi.org/10.1093/ajcp/aqaa198
  77. Egemen, D., Cheung, L. C., Chen, X., Demarco, M., Perkins, R. B., Kinney, W., Poitras, N., Befano, B., Locke, A., Guido, R. S., Wiser, A. L., Gage, J. C., Katki, H. A., Wentzensen, N., Castle, P. E., Schiffman, M., & Lorey, T. S. (2020). Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of lower genital tract disease, 24(2), 132-143. https://doi.org/10.1097/LGT.0000000000000529
  78. Rodríguez, A. C., Solomon, D., Herrero, R., Hildesheim, A., Gon­zá­lez, P., Wacholder, S., Porras, C., Jiménez, S., Schiffman, M., & CVT Group (2013). Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment. American journal of epidemiology, 178(5), 752-760. https://doi.org/10.1093/aje/kwt047

Downloads

Published

2023-04-28

How to Cite

1.
Pavliuchenko MI, Krut YY, Siusiuka VH, Deinichenko OV. Modern approaches to cervical cancer screening (a review). Pathologia [Internet]. 2023Apr.28 [cited 2026May12];20(1):85-93. Available from: https://pat.zsmu.edu.ua/article/view/264035

Issue

Vol. 20 No. 1 (2023)

Section

Review

License

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Лицензия Creative Commons